<- Go Home
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Market Cap
$133.3M
Volume
169.3K
Cash and Equivalents
$62.4M
EBITDA
-$74.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$19.58
52 Week Low
$3.35
Dividend
N/A
Price / Book Value
1.53
Price / Earnings
-1.90
Price / Tangible Book Value
1.53
Enterprise Value
$42.4M
Enterprise Value / EBITDA
-0.57
Operating Income
-$74.7M
Return on Equity
58.79%
Return on Assets
-36.54
Cash and Short Term Investments
$91.2M
Debt
$336.0K
Equity
$87.0M
Revenue
N/A
Unlevered FCF
-$34.4M
Sector
Pharmaceuticals
Category
N/A